Key facts
- RevMedica’s last known valuation is $23.5M (Jun 2023).
- It has raised $20.2M across 1 recorded rounds; the latest was Early Stage VC ($14.2M) in May 2023.
- Notable investors include US National Science Foundation, MassChallenge, Connecticut Innovations, VentureWell, Accelerator for Biosciences in Connecticut — 9 tracked in total.
- RevMedica has filed 1 Form D with the SEC, most recently Jun 2023 ($14.2M sold to 41 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for RevMedica
Funding rounds
1 roundsAbout RevMedica
Operator of a medtech company intended to revolutionize the way surgeons approach soft tissue management. The company provides critical decision-making information along with superior performance and a smart balance of features and easing the way surgeons approach soft tissue management, enabling surgeons to extend their tactile reach to the target tissue with AI guidance, minimize inefficient workflows, reduce costs and eliminate toxic waste disposal.
- Sector
- Healthcare
- HQ
- Middletown, CT, United States
- Founded
- 2017
- Employees
- 14
- Website
- revmedica.com/
- Ownership
- Privately Held (backing)
RevMedica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RevMedica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RevMedica in its N-PORT filings yet. We sweep new filings monthly.